OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM

This study is testing OriCAR-017, a type of CAR-T cell therapy, for people with relapsed or refractory multiple myeloma — a blood cancer that has come back or stopped responding to treatment. This particular CAR-T therapy targets a protein called GPRC5D found on myeloma cells. **You may be eligible if...** - You have multiple myeloma that has come back or is not responding to treatments - You have received prior standard treatments as required by the protocol - Your myeloma cells test positive for the GPRC5D protein (by flow cytometry or biopsy) - Your expected survival is more than 12 weeks and you are in reasonable health (ECOG 0-2) **You may NOT be eligible if...** - Your myeloma cells do not express the GPRC5D target protein - You have active infections, serious organ damage, or uncontrolled health problems - You have received prior CAR-T therapy targeting GPRC5D - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.